Treatment of disseminated intravascular coagulation with gabexate mesilate.
Gabexate mesilate (FOY) was used to treat 215 patients with disseminated intravascular coagulation (DIC) and 146 patients with a predisposition to DIC (pre-DIC). Sixty percent of DIC patients and 48% of pre-DIC patients exhibited pretreatment organ failure, which resolved after FOY treatment in 16% of DIC patients and 17% of pre-DIC patients. Seventy percent of DIC patients and 49% of pre-DIC patients had a pretreatment bleeding tendency that was ameliorated by FOY treatment in 32% of DIC patients and 30% of pre-DIC patients. Comparison of pretreatment and posttreatment hemostatic studies of the DIC patients revealed that platelet count and levels of fibrinogen degradation products (FDP), thrombin-antithrombin-III complex, and FDP-D-dimer decreased significantly; fibrinogen level increased markedly; and prothrombin time was prolonged. DIC scores were significantly lowered in both leukemic and nonleukemic patients from the third day of treatment with FOY. Among leukemic DIC patients, 59% showed complete remission (CR), 21% partial remission (PR), and 7% exacerbation of their condition; 46% of the nonleukemic DIC patients demonstrated CR, 17% PR, and 17% exacerbation. Of the leukemic pre-DIC patients, 59% showed improvement and 7% exacerbation, whereas 55% of the nonleukemic pre-DIC patients showed improvement and 27% exacerbation.
Tamaki
S
S
Second Department of Internal Medicine, Mie University School of Medicine, Japan.
Wada
H
H
Hiyoyama
K
K
Shimura
M
M
Minamikawa
K
K
Wakita
Y
Y
Nakase
T
T
Ohiwa
M
M
Kaneko
T
T
Iwasaki
E
E
D004211:Disseminated Intravascular Coagulation / Q000188:drug therapy*; D005260:Female; D016670:Gabexate / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D013927:Thrombosis / Q000150:complications
D016670:Gabexate